Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: A prospective dose-adjusted drug interaction strategy

Journal of Clinical Psychopharmacology

Volumn 25, Issue 2, 2005, Pages 170-174

  Albers, Lawrence J ^a,g   Ozdemir, Vural ^a,b   Marder, Stephen R ^c,d   Raggi, Maria Augusta ^e   Aravagiri, Manickam ^c   Endrenyi, Laszlo ^f   Reist, Christopher ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b S CA Inst for Res and Education   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Education   (United States)

^e UNIVERSITY OF BOLOGNA   (Italy)

^f UNIVERSITY OF TORONTO   (Canada)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' N NOROLANZAPINE; CYTOCHROME P450 1A2; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; FLUVOXAMINE; OLANZAPINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CIGARETTE SMOKING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMETHYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG POTENTIATION; ENDOCRINE DISEASE; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPOTHESIS; LIPID BLOOD LEVEL; LOW DRUG DOSE; MALE; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TIME SERIES ANALYSIS;

BENZODIAZEPINES; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FLUVOXAMINE; HUMANS; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS;

EID: 15444365781     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000155825.97703.01     Document Type: Article

References (27)

1. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. Am J Psychiatry. 1993;150:1447-1465.
2. Quick JD. Ensuring access to essential medicines in the developing countries: a framework for action. Clin Pharmacol Ther. 2003;73:279-283.
3. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177-193.
4. Albers LJ, Ozdemir V. Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics. Curr Med Chem. 2004;11:297-312.
5. Brown CS, Markowitz JS, Moore TR, et al. Atypical antipsychotics. Part II: adverse effects, drug interactions, and costs. Ann Pharmacother. 1999;33:210-217.
6. Alfaro CL. Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown. Psychopharmacol Bull. 2001;35:80-93.
7. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol. 2003;23:119-127.
8. Shirley KL, Hon YY, Penzak SR, et al. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology. 2003;28:961-966.
9. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 1996;276:658-666.
10. Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24:518-526.
11. Hiemke C, Peled A, Jabarin M, et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol. 2002;22:502-506.
12. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther. 1991;49:44-48.
13. Aravagiri M, Ames D, Wirshing WC, et al. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit. 1997;19:307-313.
14. Raggi MA, Mandrioli R, Sabbioni C, et al. Determination of olanzapine and desmethylolanzapine in plasma of schizophrenic patients by an improved HPLC method with amperometric detection. Chromatographia. 2001;54:203-207.
15. Brett MA, Dierdorf HD, Zussman BD, et al. Determination of paroxetine in human plasma, using high performance liquid chromatography with fluorescence detection. J Chromatogr. 1987;419:438-444.
16. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-3224.
17. Lu ML, Lane HY, Chen KP, et al. Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatry. 2000;61:594-599.
18. Florea NR, Capitano B, Nightingale CH, et al. Beneficial pharmacokinetic interaction between cyclosporine and itraconazole in renal transplant recipients. Transplant Proc. 2003;35:2873-2877.
19. Center for Drug Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. March 19, 2003. Available at: http://www.fda.gov/cder/guidance/ 5356fnl.pdf/. Accessed January 13, 2005.
20. Weigmann H, Gerek S, Zeisig A, et al. Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit. 2001;23:410-413.
21. Perry PJ, Lund BC, Sanger T, et al. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21:14-20.
22. de Jong J, Hoogen boom B, van Troostwijk LD, et al. Interaction of olanzapine with fluvoxamine. Psychopharmacology (Berl). 2001;155:219-220.
23. Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther. 2002;71:141-152.
24. Spigset O, Granberg K, Hagg S, et al. Non-linear fluvoxamine disposition. Br J Clin Pharmacol. 1998;45:257-263.
25. Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol. 1993;45:1211-1214.
26. Yao C, Kunze KL, Kharasch ED, et al. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther. 2001;70:415-424.
27. von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol. 1995;15:125-131.